Sabine Irtan1, Louise Galmiche-Rolland2, Caroline Elie3, Daniel Orbach4, Alain Sauvanet5, Dominique Elias6, Florent Guérin7, Carole Coze8, Cécile Faure-Conter9, François Becmeur10, Martine Demarche11, René Benoît Galifer12, Marie Agnès Galloy13, Guillaume Podevin14, Didier Aubert15, Christian Piolat16, Pascal De Lagausie17, Sabine Sarnacki1. 1. Department of Pediatric Surgery, Necker Enfants-Malades Hospital-Université Paris Descartes, Sorbonne Paris Cite, Paris, France. 2. Department of Pathology, Necker Enfants-Malades Hospital-Université Paris Descartes, Sorbonne Paris Cite, Paris, France. 3. Clinical Research Unit/Clinical Investigation Centre, Necker Enfants-Malades Hospital, Paris, France. 4. Department of Pediatrics, Adolescents, Young Adults, Institut Curie, Groupe Fracture, French Rare Pediatric Tumors Group, Paris, France. 5. Department of Hepato-Pancreato-Biliary Surgery, Pôle des Maladies de l'Appareil Digestif (PMAD), AP-HP, Hôpital Beaujon, Clichy, France. 6. Department of Surgical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. 7. Department of Pediatric Surgery, Hôpitaux Universitaires Paris-Sud, Bicêtre Hospital, Université Paris XI, Le Kremlin-Bicêtre, France. 8. Department of Pediatric Hematology-Oncology, Aix-Marseille Univ and APHM, Hôpital d' Enfants de La Timone, Marseille, France. 9. Department of Pediatrics, Institut Leon Bérard, Lyon, France. 10. Department of Pediatric Surgery, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 11. Department of Pediatric Surgery, CHR de la Citadelle, Liège, Belgium. 12. Department of Pediatric Surgery, Lapeyronie-Arnaud de Villeneuve Hospital, Montpellier, France. 13. Department of Pediatric Surgery, Children's Hospital Nancy-Brabois University Hospital, Vandoeuvre-lès-Nancy, France. 14. Department of Pediatric Surgery, University Hospital, Angers, France. 15. Department of Pediatric Surgery, University Hospital, Besançon, France. 16. Department of Pediatric Surgery, University Hospital, Grenoble, France. 17. Department of Pediatric Surgery, Aix-Marseille Univ and APHM, Hôpital d'Enfants de La Timone, Marseille, France.
Abstract
BACKGROUND: Solid pseudopapillary neoplasms of the pancreas (SPPN) can relapse very late, but little is known about risk factors for recurrence and optimal treatment. We aimed to identify risk factors for recurrence and to analyze treatment modalities in all French pediatric cases of SPPN over the past 20 years. MATERIAL AND METHODS: Data were collected from pediatric oncologists and surgeons, and also from adult pancreatic surgeons in order to identify late recurrences. RESULTS: Fifty-one patients (41 girls) were identified. Median age at diagnosis was 13.1 years [8.7-17.9]. Abdominal pain was the commonest presenting symptom (32/49, 65%). The tumor was located in the pancreatic head in 24 patients (47%). Preoperative biopsy or cytology was performed in 14 cases (28%). All patients were operated with a median of 23 days [0-163] after diagnosis. The rate of postoperative morbidity was 29%. With a median follow-up of 65 months [0.3-221], the overall and event-free survival was 100% and 71%, respectively. Seven patients (13.7%) relapsed with a median of 43 months [33-94] after initial surgery. Six were treated surgically, either alone (n = 3) or with perioperative chemotherapy (n = 2) or hyperthermic intraperitoneal chemotherapy (n = 1). One patient in whom further treatment was not feasible was still alive at last news. Risk factors for recurrence were positive surgical margins (P = 0.03) and age less than 13.5 years at diagnosis (P = 0.03). CONCLUSIONS: SPPN recurrence in this pediatric series was a rare and late event that did not undermine overall survival. Complete surgical removal of recurrent tumors appears to be the best option.
BACKGROUND: Solid pseudopapillary neoplasms of the pancreas (SPPN) can relapse very late, but little is known about risk factors for recurrence and optimal treatment. We aimed to identify risk factors for recurrence and to analyze treatment modalities in all French pediatric cases of SPPN over the past 20 years. MATERIAL AND METHODS: Data were collected from pediatric oncologists and surgeons, and also from adult pancreatic surgeons in order to identify late recurrences. RESULTS: Fifty-one patients (41 girls) were identified. Median age at diagnosis was 13.1 years [8.7-17.9]. Abdominal pain was the commonest presenting symptom (32/49, 65%). The tumor was located in the pancreatic head in 24 patients (47%). Preoperative biopsy or cytology was performed in 14 cases (28%). All patients were operated with a median of 23 days [0-163] after diagnosis. The rate of postoperative morbidity was 29%. With a median follow-up of 65 months [0.3-221], the overall and event-free survival was 100% and 71%, respectively. Seven patients (13.7%) relapsed with a median of 43 months [33-94] after initial surgery. Six were treated surgically, either alone (n = 3) or with perioperative chemotherapy (n = 2) or hyperthermic intraperitoneal chemotherapy (n = 1). One patient in whom further treatment was not feasible was still alive at last news. Risk factors for recurrence were positive surgical margins (P = 0.03) and age less than 13.5 years at diagnosis (P = 0.03). CONCLUSIONS: SPPN recurrence in this pediatric series was a rare and late event that did not undermine overall survival. Complete surgical removal of recurrent tumors appears to be the best option.
Authors: Simone de Campos Vieira Abib; Chan Hon Chui; Sharon Cox; Abdelhafeez H Abdelhafeez; Israel Fernandez-Pineda; Ahmed Elgendy; Jonathan Karpelowsky; Pablo Lobos; Marc Wijnen; Jörg Fuchs; Andrea Hayes; Justin T Gerstle Journal: Ecancermedicalscience Date: 2022-02-17
Authors: Ahmed ElHaddad; Paolo Gasparella; Christoph Castellani; Georg Singer; Erich Sorantin; Klara Zach; Holger Till Journal: European J Pediatr Surg Rep Date: 2019-08-21